Table 2.
Factor | No. of Patients | Patients With Optimal Response |
Univariate Analysis |
Multivariate Analysis |
|||||
---|---|---|---|---|---|---|---|---|---|
No. | % | P | OR | 95% CI | P | OR | 95% CI | ||
Age, years | |||||||||
> 60 | 80 | 24 | 30.0 | .972 | 0.99 | 0.53 to 1.81 | |||
≤ 60 | 129 | 39 | 30.2 | ||||||
Sex | |||||||||
Male | 124 | 32 | 25.8 | .100 | 0.61 | 0.33 to 1.10 | |||
Female | 85 | 31 | 36.5 | ||||||
No. of liver metastases | |||||||||
Solitary | 78 | 23 | 29.5 | .873 | 0.95 | 0.51 to 1.76 | |||
Multiple | 131 | 40 | 30.5 | ||||||
Size of largest metastasis before chemotherapy, cm* | |||||||||
≤ 3 | 115 | 42 | 36.5 | .025 | 2.00 | 1.09 to 3.75 | .025 | 2.12 | 1.10 to 4.19 |
> 3 | 94 | 21 | 22.3 | ||||||
Differentiation of tumor | |||||||||
Well/moderate | 177 | 55 | 31.1 | .484 | 1.35 | 0.59 to 3.39 | |||
Poor | 32 | 8 | 25.0 | ||||||
Fluorouracil-based chemotherapy regimen | |||||||||
Irinotecan | 69 | 11 | 17.5 | .001 | 0.32 | 0.15 to 0.65 | .950 | ||
Oxaliplatin | 140 | 52 | 37.1 | ||||||
Bevacizumab | |||||||||
Yes | 108 | 51 | 47.2 | < .001 | 6.64 | 3.35 to 14.0 | < .001 | 6.71 | 2.97 to 16.6 |
No | 101 | 12 | 11.9 |
Abbreviation: OR, odds ratio.
Cutoff value was decided by receiver operating characteristic curve analysis for optimal response.